Estrogen Receptor-Beta Gene Polymorphism in women with Breast Cancer at the Imam Khomeini Hospital Complex, Iran

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Abbasi, Sakineh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR BETA;

ADULT; ALLELE; ARTICLE; BLOOD GROUP ABO SYSTEM; BODY MASS; BREAST CANCER; CANCER RISK; CODON; CONTROLLED STUDY; EXON; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE EXPRESSION; GENE FREQUENCY; GENERAL HOSPITAL; GENETIC ASSOCIATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENARCHE; ONSET AGE; POLYMERASE CHAIN REACTION; RACE; RELATIVE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; BREAST TUMOR; CASE CONTROL STUDY; GENETICS; GENOTYPE; MIDDLE AGED; PATHOLOGY; RISK;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN RECEPTOR BETA; FEMALE; GENOTYPE; HUMANS; IRAN; LYMPHATIC METASTASIS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 77954296706     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-109     Document Type: Article

References (44)

1. McPherson K, Steel C, Dixon J. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000, 321:624-628. 10.1136/bmj.321.7261.624, 1118507, 10977847.
2. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A. Breast cancer in Iran: a review of 903 case records. Public Health 2000, 114:143-145. 10.1016/S0033-3506(00)00324-3, 10800155.
3. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, Ebrahimi M. Breast Cancer in Iran: An Epidemiological Review. Breast J 2007, 13(4):383-391. 10.1111/j.1524-4741.2007.00446.x, 17593043.
4. Anderson E, Clarke R, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 1998, 3:23-35. 10.1023/A:1018718117113, 10819502.
5. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 2002, 4:197-201. 10.1186/bcr452, 138744, 12223124.
6. Newman B, Mu H, Butler L, Millikan R, Moorman P, King M. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998, 279:915-921. 10.1001/jama.279.12.915, 9544765.
7. Vehmanen P, Friedman L, Eerola H, Sarantaus L, Pyrhönen S, Ponder B, Muhonen T, Nevanlinna H. A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 1997, 60:1050-1058. 1712419, 9150152.
8. Whittemore A, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997, 60:496-504. 1712497, 9042908.
9. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85. 10.1056/NEJM200007133430201, 10891514.
10. de Jong M, Nolte I, te Meerman G, van der Graaf W, Oosterwijk J, Kleibeuker J, Schaapveld M, de Vries EG. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 2002, 39:225-242. 10.1136/jmg.39.4.225, 1735082, 11950848.
11. Jordan V. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004, 5:207-213. 10.1016/S1535-6108(04)00059-5, 15050912.
12. Hanstein B, Djahansouzi S, Dall P, Beckmann M, Bender H. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol 2004, 150:243-255. 10.1530/eje.0.1500243, 15012607.
13. Tempfer C, Schneeberger C, Huber J. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 2004, 5:57-65. 10.1517/phgs.5.1.57.25687, 14683420.
14. Lymberis S, Parhar P, Katsoulakis E, Formenti S. Pharmacogenomics and breast cancer. Pharmacogenomics 2004, 5:31-55. 10.1517/phgs.5.1.31.25686, 14683419.
15. Bland K, Copeland E. The breast: comprehensive management of benign and malignant disorders. 2004, Saunders St. Louis, 3.
16. Kallel I, Rebai M, Khabir A, Farid NR, Rebaï A. Genetic Polymorphisms in the EGFR (R521K) and Estrogen Receptor (T594T) Genes, EGFR and ErbB-2 Protein Expression, and Breast Cancer Risk in Tunisia. J Biomed Biotechnol 2009, 2009:753683. Epub 2009 Jul 14, 2711625, 19636371.
17. Iwase H, Greenman J, Barnes D, Hodgson S, Bobrow L, Mathew C. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Cancer Lett 1996, 108:179-184. 10.1016/S0304-3835(96)04406-0, 8973592.
18. Curran J, Lea R, Rutherford S, Weinstein S, Griffiths L. Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer. Int J Cancer 2001, 95:271-275. 10.1002/1097-0215(20010720)95:4<271::AID-IJC1046>3.0.CO;2-D, 11400122.
19. Vasconcelos A, Medeiros R, Veiga I, Pereira D, Carrilho S, Palmeira C, Azevedo C, Lopes CS. Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J 2002, 8:226-229. 10.1046/j.1524-4741.2002.08407.x, 12100115.
20. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007, 87:905-931. 10.1152/physrev.00026.2006, 17615392.
21. Wang J, Higuchi R, Modugno F, Li J, Umblas N, Lee J, Lui LY, Ziv E, Tice JA, Cummings SR, Rhees B. Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 2007, 106:273-280. 10.1007/s10549-007-9497-8, 17268813.
22. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007, 39:655-660. 10.1038/ng2006, 17417639.
23. Roodi N, Bailey L, Kao W, Verrier C, Yee C, Dupont W. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995, 87:446-451. 10.1093/jnci/87.6.446, 7861463.
24. Azimi C, Abbasi S. Genetic polymorphisms in the estrogen receptor-α gene codon 325(CCC→CCG) and risk of breast cancer among Iranian women: a case control study. Med J Islamic Republic of Iran 2009, 23(2):75-82.
25. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Esquifino AI, Cardinali DP, Maestroni GJ. Melatonin, environmental light, and breast cancer. Breast Cancer Res Treat 2008, 108(3):339-350. 10.1007/s10549-007-9617-5, 17541739.
26. Surekha D, Sailaja K, Nageswara Rao D, Raghunadharao D, Vishnupriya S. Oestrogen receptor beta (ERβ) polymorphism and its influence on breast cancer risk. J Gent 2009, 88(2):261-266.
27. Iwasaki M, Hamada GS, Nishimoto IN, Netto MM, et al. Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. Official J Japan Cancer Assoc 2009, 100(5):927-933.
28. Rozenkranz K, Hinney A, Ziegler A, Herman H, Fichter M, et al. Systematic mutation screening of estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants. J Clin Endocrinol Metab 1998, 83:4524-4527. 10.1210/jc.83.12.4524, 9851804.
29. Zheng S, Zheng W, Chang B, Shu X, Cai Q, Yu H, Dai Q, Xu J, Gao YT. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res 2003, 63:7624-7629.
30. Maguire P, Margolin S, Skoglund J, Sun X, et al. Gustafsson J. Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer. Breast Cancer Res Treat 2005, 94(2):145-152. 10.1007/s10549-005-7697-7, 16261413.
31. Cox DG, Philip Bretsky P, Peter Kraft P, Paul Pharoah P. Haplotypes of the Estrogen receptor beta (ESR2) gene and breast cancer risk. Int J Cancer 2008, 122(2):387-392. 10.1002/ijc.23127, 2796078, 17935138.
32. Forsti A, Zhao C, Israelsson E, Dahlman-Wright K, Gustafsson JA, Hemminki K. Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res Treat 2003(79):409-413.
33. Treeck O, Elemenler E, Kriener C, Horn F, Springwald A, Hartmann A, Ortmann O. Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 2009, 114(3-5):207-11. 10.1016/j.jsbmb.2009.02.012, 19429453.
34. Abbasi S. Polymorphisms in estrogen receptor -alpha and beta genes in breast cancer patients from Imam Khomeini Hospital. [Ph.D thesis] 2008, Malaysia: Universiti Putra Malaysia.
35. Abbasi S, Ismail P, Othman F, Rosli R, Azimi C. Estrogen receptor-α (ESR1) gene, codon 594 (G3242A) polymorphism among Iranian women with breast cancer: a case control study. Asian J Scie Res 2009, 2(1):51-60.
36. Westberg L, Hakansson A, melke J, Shahabi HN, Nilsson S, et al. Association between the estrogen receptor beta gene and age at onset of Parkinson disease. Psychoneuroendocrinolgy 2004, 29:993-998.
37. Rosenkranz K, Hinney A, Ziegler A. Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants. J Clin Endocrinol Metab 1998, 83:4524-4527. 10.1210/jc.83.12.4524, 9851804.
38. Sundarrajan C, Liao WX, Roy AC, Ng SC. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab 2001, 86:135-139. 10.1210/jc.86.1.135, 11231990.
39. Ogawa S, Hosoi T, Shiraki M, Orimo H, Emi M, Muramatsu M, Ouchi Y, Inoue S. Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 2000, 269:537-541. 10.1006/bbrc.2000.2285, 10708589.
40. KupierKupier GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson J. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997, 3:863-870.
41. Fisher E, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993, 71:2507-2514. 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0, 8453574.
42. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991, 68:2142-2149. 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D, 1913453.
43. Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Bruzzi P. Prognostic role of lymph-node level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg Oncol 1998, 24:104-109. 10.1016/S0748-7983(98)91381-6, 9591024.
44. Goldhirsch A, Wood W, Senn H, Glick J, Gelber R. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995, 87:1441-1445. 10.1093/jnci/87.19.1441, 7674331.